

CLAIMS

1. A compound comprising one part conferring cytotoxic and/or anti-cancer effects to the compound and one part conferring specific binding affinity towards a CYP2W1-molecule according to SEQ ID No: 8 to the compound.
2. A pharmaceutical composition comprising a compound according to claim 1 and pharmaceutically acceptable excipients and/or carriers.
3. An antibody, preferably a monoclonal antibody, binding specifically to CYP2W1.
4. Use of the cytochrome P450 enzyme CYP2W1 and genetic variants thereof as a drug target in cancer therapy, preferably in the treatment of lung tumours, colon tumours and/or ovarian tumours.
5. A method of providing therapeutic agents for cancer therapy, comprising screening for such agents by using CYP2W1 as a drug target.
6. A method according to claim 5, comprising screening for therapeutic agents modulating, preferably increasing, the activity of CYP2W1.
7. A method of treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a substance activated by the enzyme CYP2W1 and/or inducing the enzyme CYP2W1 and/or the compound according to claim 1.
8. DNA-molecule with nucleotide sequence according to SEQ ID NO: 10.
9. Use of a DNA-molecule according to claim 8 in the manufacture of a medicament.

10. A method of providing therapeutic agents for cancer therapy, comprising screening for such agents modulating expression of genes regulated by the CYP2W1 promoter according to SEQ ID NO: 10.